"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.
Descriptor ID |
D007521
|
MeSH Number(s) |
D08.811.682.047.820.475
|
Concept/Terms |
Isocitrate Dehydrogenase- Isocitrate Dehydrogenase
- Dehydrogenase, Isocitrate
- NAD Isocitrate Dehydrogenase
- Dehydrogenase, NAD Isocitrate
- Isocitrate Dehydrogenase, NAD
- Isocitrate Dehydrogenase (NAD+)
|
Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".
This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 |
2009 | 4 | 0 | 4 |
2010 | 0 | 3 | 3 |
2011 | 8 | 1 | 9 |
2012 | 7 | 2 | 9 |
2013 | 6 | 2 | 8 |
2014 | 6 | 1 | 7 |
2015 | 8 | 4 | 12 |
2016 | 8 | 5 | 13 |
2017 | 12 | 7 | 19 |
2018 | 13 | 1 | 14 |
2019 | 3 | 8 | 11 |
2020 | 10 | 9 | 19 |
2021 | 12 | 9 | 21 |
2022 | 6 | 10 | 16 |
2023 | 2 | 13 | 15 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
-
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas. Nat Commun. 2024 Jan 25; 15(1):730.
-
The genomic alterations in glioblastoma influence the levels of CSF metabolites. Acta Neuropathol Commun. 2024 Jan 19; 12(1):13.
-
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 2023 Dec 11; 147(1):3.
-
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.
-
Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathol Commun. 2023 11 02; 11(1):175.
-
Prognostic value of integrative genomic approaches for IDH-mutant gliomas. Neuro Oncol. 2023 11 02; 25(11):2042-2043.
-
Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells. Cancer Sci. 2024 Jan; 115(1):197-210.
-
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148.
-
Flavopiridol Suppresses Cell Proliferation and Migration and Induces Apoptotic Cell Death by Inhibiting Oncogenic FOXM1 Signaling in IDH Wild-Type and IDH-Mutant GBM Cells. Mol Neurobiol. 2024 Feb; 61(2):1061-1079.